

| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 1,309.57 | 1,159.77 | 1,067.51 | 1,159.77 | 931.27 |
| Total Expenses | 1,157.89 | 1,106.79 | 1,101.98 | 1,062.63 | 795.32 |
| Profit Before Tax | 122.33 | 54.34 | -38.28 | 102.26 | 195.05 |
| Profit After Tax | 78.30 | 31.96 | -30.97 | 60.58 | 146.20 |
| Operating Profit After Depreciation | 227.21 | 144.80 | 24.18 | 138.30 | 157.82 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,777.09 | 1,700.64 | 1,665.62 | 1,657.98 | 1,349.69 |
| Total Non Current Assets | 2,325.04 | 2,216.38 | 2,134.37 | 1,988.30 | 1,729.60 |
| Total Current Assets | 985.67 | 876.83 | 769.55 | 887.19 | 902.77 |
| Total Assets | 3,310.71 | 3,093.20 | 2,903.93 | 2,875.50 | 2,632.37 |
| Total Shareholder's Fund | 2,372.24 | 1,808.69 | 1,783.28 | 1,822.19 | 1,478.67 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 132.18 | 136.67 | 179.92 | 105.13 | 46.93 |
| Net Cash Used In Investing Activities | -198.06 | -170.76 | -232.27 | -285.50 | -404.28 |
| Net Cash Used In Financing Activities | 62.65 | 46.78 | 45.80 | 82.86 | 436.37 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 561.18 | 398.90 | 316.35 | 397.81 | 289.30 |
| Total Expenses | 408.20 | 350.36 | 359.08 | 379.14 | 252.03 |
| Profit Before Tax | 107.24 | 38.09 | -58.28 | 27.49 | 90.21 |
| Profit After Tax | 69.80 | 26.94 | -49.48 | 20.16 | 65.09 |
| Operating Profit After Depreciation | 159.58 | 65.80 | -21.90 | 27.73 | 43.34 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 811.63 | 804.65 | 793.52 | 806.33 | 826.06 |
| Total Non Current Assets | 2,529.38 | 2,041.66 | 1,882.41 | 2,586.68 | 1,737.50 |
| Total Current Assets | 477.29 | 376.97 | 636.25 | 309.44 | 779.90 |
| Total Assets | 3,006.66 | 2,418.62 | 2,518.66 | 2,896.12 | 2,517.39 |
| Total Shareholder's Fund | 2,700.59 | 2,142.72 | 2,117.58 | 2,065.67 | 1,637.83 |
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | -19.06 | 9.55 | 2.08 | 173.87 | 69.63 |
| Net Cash Used In Investing Activities | -431.06 | 155.49 | -94.83 | -378.97 | -238.13 |
| Net Cash Used In Financing Activities | 450.09 | -163.07 | 87.68 | 97.23 | 255.58 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 436.99 | 410.28 | 369.97 | 321.46 | 330.82 |
| Total Expenses | 317.28 | 295.79 | 261.80 | 230.55 | 251.61 |
| Profit Before Tax | 120.44 | 60.85 | 64.43 | 49.59 | 15.27 |
| Profit After Tax | 107.79 | 44.58 | 44.07 | 46.89 | 14.51 |
| Operating Profit after Depreciation | 139.70 | 114.75 | 109.92 | 97.29 | 89.14 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 201.11 | 165.70 | 134.93 | 92.43 | 126.21 |
| Total Expenses | 141.32 | 134.70 | 95.79 | 75.44 | 88.19 |
| Profit Before Tax | 78.02 | 23.79 | 38.92 | 14.78 | -9.91 |
| Profit After Tax | 70.96 | 15.93 | 30.83 | 20.70 | -5.63 |
| Operating Profit after Depreciation | 66.68 | 42.29 | 56.08 | 34.78 | 48.66 |
₹1.0/Share
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,794.30 | ₹4,30,512.67 |
| Divis Laboratories Ltd | ₹6,651.25 | ₹1,76,569.79 |
| Torrent Pharmaceuticals Ltd | ₹4,570 | ₹1,54,669.57 |
| Cipla Ltd | ₹1,383 | ₹1,11,725.01 |
| Zydus Lifesciences Ltd | ₹1,105.65 | ₹1,11,254.26 |
| Fund Name | AUM |
|---|---|
| Aditya Birla SL Pharma & Healthcare Fund | 2.92% |
| HDFC Pharma and Healthcare Fund | 2.28% |
| Aditya Birla SL Manufacturing Equity Fund | 1.31% |
| ICICI Pru Export and Services Fund | 0.82% |
| ICICI Pru ELSS Tax Saver Fund | 0.76% |
03 Jun 2026, 11:07 am
Of Rs 0.6 per share
22 May 2026, 07:27 pm
On 22 May 2026
15 May 2026, 01:49 pm
With effect from 23 April 2026
23 Apr 2026, 11:58 am
Shilpa Medicare said that its subsidiary Shilpa Biologicals and SteinCares have entered into a strategic licensing agreement to commercialize a biosimilar across Latin America.
24 Feb 2026, 11:45 am

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Get started with us today and
start building your wealth journey
*By clicking, I agree to the T&C and Whatsapp updates.

Congratulations,
Your Digital savings bank account opening journey is complete.